| **Study Reference** | **Participant Characteristics** | **Intervention; Duration** | **Discontinuations due to AE****Risk in Treatment Group; Risk in Control Group****(RR [95% CI])** | **Serious AEs****Risk in Treatment Group; Risk in Control Group****(RR [95% CI])** | **Gastrointestinal Adverse Eventsa****Risk in Treatment Group; Risk in Control Group****(RR [95% CI])** | **Other Adverse Events** | **Quality Rating** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Lewiecki et al, 2007236a | Postmenopausal women with lumbar spine BMD T-scores of-1.8 to -4.0 or femoral neck/total hip T-scores of -1.8 to -3.5 | Denosumab for 24 months; dosed at 6, 14, or 30 mgsubcutaneously every 3 months, or 14, 60, 100, or 210 mg subcutaneously every 6 months, alternating with placebo |  11/314; 1/46 (1.61 [0.21 to 12.19]) | 42/314; 4/46 (1.54 [0.58 to 4.09]) | 1/314; 0/46 | Death1/314; 0/46, Cardiac disorder6/314; 2/46(0.45 [0.02 to 10.83])Serious infections6/314; 0/46 | Fair |
| Bone et al, 2008237a | Postmenopausal women with a lumbar spine BMD T scorebetween -1.0 and -2.5 | Denosumab 60 mg every 6 monthsfor 24 months subcutaneously (last dose at 18 months) | 1/164; 2/165 (0.50 [0.05 to 5.49]) | 18/164; 9/165 (2.01 [0.93 to 4.35]) | 2/164; 0/165 | Deaths0/164; 0/165RR not calculableRash14/164; 5/165 (2.82 [1.04 to 7.64])Serious infections8/164; 1/165 | Fair |
| Cummings et al, 2009238; Watts et al, 2012314 | Women between the ages of 60 and 90 years witha bone mineral density T score of less than −2.5at the lumbar spine or total hip | Denosumab 60 mg every 6 months for 36 months subcutaneously | 93/3886; 81/3876 (1.15 [0.85 to 1.54]) | 1004/3886; 972/3876 (1.03 [0.95 to 1.11]) | NR | Deaths70/3886; 90/3876 (0.78 [0.57 to 1.06])Osteonecrosis of the jaw0/3886; 0/3876RR not calculableCardiovascular events186/3886; 178/3876 (1.04 [0.85 to 1.27])Eczema118/3886; 65/3876 (1.81 [1.34 to 2.44])Serious infections159/3886;133/3876 (1.19 [0.95 to 1.49])Serious skin infections (cellulitis and erysipelas)15/3886; 1/3876 (14.96 [1.98 to 113.21]) | Fair |
| Nakamura et al., 2012239 | Ambulatory Japenese postmenopausal women 80 years or younger, who had osteoporosis, and a BMD T-score of -2.5 to -4.0 at the lumbar 1 to lumbar 4 spine or -2.5 to -3.5 at either the femoral neck or total hip | Denosumab 14 mg subcutaneously every 6 months for 12 months; or denosumab 60 mg subcutaneously every 6 months for 12 months; or denosumab 100 mg subcutaneously every 6 months for 12 months; or placebo every 6 months for 12 months | NR | Denosumab 14 mg subcutaneously every 6 months for 12 months: 6/53denosumab 60 mg subcutaneously every 6 months for 12 months: 4/54denosumab 100 mg subcutaneously every 6 months for 12 months: 2/50placebo every 6 months for 12 months: 4/55 | NR | NR | Fair |

**Abbreviations:** CI=confidence interval; mg=milligram; NR=not reported; RR=risk ratio.